STK-012 + pembrolizumab

STK-012 + pembrolizumab is a combination therapy being investigated for the treatment of advanced solid tumors. STK-012 is a modified form of interleukin-2 (IL-2), a cytokine normally produced by the immune system. It has been engineered in the laboratory to potentially activate the immune system to attack cancer cells. Pembrolizumab (KEYTRUDA) is an FDA-approved immune checkpoint inhibitor that may help turn on the immune system to attack cancer cells. The combination is being studied to determine the highest dose of STK-012 that can be safely given with a standard dose of pembrolizumab in patients with advanced solid tumors.